The Sioux Community Cancer Consortium (SCCC) is a two component, community based clinical cancer research organization. The SCCC was founded in 1983 and has been a continuing clinical community oncology program of the National Cancer Institute (NCI) since that time. The two major components of the SCCC are in Sioux Falls, SD and Sioux City, IA. These component sites are separated by a mere ninety miles on Interstate 29 in the rural Midwest. The SCCC is the only immediately available source of clinical cancer research sponsored by the NCI in Sioux Falls, SD and Sioux City, IA and their regional referral areas. The geographic catchment area for the SCCC covers approximately 105,000 square miles in the southeastern section of South Dakota, the southwestern section of Minnesota, the northwestern section of Iowa and the northeastern section of Nebraska. The primary research base for the SCCC will remain the North Central Cancer Treatment Group (NCCTG) with affiliate status with the Eastern Cooperative Oncology Group (EC0G) through the NCCTG and affiliate status with the Children's Cancer Study Group (CCSG) through Mayo Clinic's membership in the CCSG. Specialty group affiliation with the National Surgical Adjuvant Breast and Bowel Project (NSABP) will continue along with involvement in the Breast Cancer Prevention Trial (BCPT). Involvement in the Prostate Cancer Prevention Trial (PCPT) is established and the program is in development. The continued specific objective of this application is to continue to make available clinical cancer treatment and cancer control research protocols in our area. One of the goals of the SCCC is to achieve 150 credits for clinical cancer treatment protocols and 50 credits for cancer control research protocols. The SCCC consists of fourteen core investigators in medical oncology, radiation oncology, gynecologic oncology and pediatric oncology. There are a number of supporting physicians and/or investigators in the surgery, pathology, and medical practice arena. This is a realistic goal based on the past accomplishments of the SCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035103-15
Application #
2712566
Study Section
Special Emphasis Panel (SRC (74))
Program Officer
Dunn, Barbara K
Project Start
1987-08-30
Project End
1999-05-31
Budget Start
1998-09-17
Budget End
1999-05-31
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Central Plains Clinic, Ltd.
Department
Type
DUNS #
City
Sioux Falls
State
SD
Country
United States
Zip Code
57105
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43

Showing the most recent 10 out of 72 publications